| 2018-BHUN-68291 | |
| Listeria monocytogenes is an opportunistic human foodborne pathogen responsible for severe systemic infection (listeriosis) which can lead to stillborn and premature births, as well as mortality in newborns, the elderly, and other immunocompromised individuals. Listeria monocytogenes is well adapted to survive in the harsh environment of the gut. Currently, there is no probiotic based protection against the Listeria monoctyogenes infection available. Researchers at Purdue University have developed a next generation probiotic bacteria that binds to intestinal epithelial cells with high affinity to the receptor protein Hsp60 on the intestinal surface. This reduces inflammatory response and prevents Listeria monocytogenes from entering the intestinal epithelial cell barrier. This probiotic bacterium improves gut epithelial barrier integrity and helps protect against disease. The number of pathogens that crossed intestinal cells is reduced significantly. In mouse studies, 90% of mice were protected from the disease. Advantages: -Protects against L. monocytogenes -Improves gut epithelial barrier integrity Potential Applications: -L. monocytogenes protection -Chronic inflammatory conditions |
|
|
|
|
Jul 1, 2019
Utility Patent
United States
11,090,357
Aug 17, 2021
Jul 2, 2018
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |